Memory Commons Logo

UVA School of Medicine

Families and Caregivers

New Drug Trial Seeks to Stop Alzheimer’s Before It Starts

By PAM BELLUCK
Published: May 15, 2012

In a clinical trial that could lead to treatments that prevent Alzheimer's, people who are genetically guaranteed to develop the disease — but who do not yet have any symptoms — will for the first time be given a drug intended to stop it, federal officials announced Tuesday.

Read More

New Alzheimer Disease Scan Approved By FDA

By AMIR KHAN
April 9, 2012 4:22 PM EDT

The FDA's approval of a new imaging test gives doctors the ability to diagnose Alzheimer's disease with some certainty for the first time. Until now, Alzheimer's disease was diagnosed by the exclusion of other conditions and could only be concretely diagnosed after death.

Alzheimer's disease is the most common form of dementia in the United States, affecting more than 5 million people, according to the Centers for Disease Control and Prevention. The number of people who suffer from the disease is expected to double every 20 years as population increases and people live longer.

Read More

Alzheimer's Disease Trigger Mimics Mad Cow Infectious Agent: Study

By ROXANNE PALMER
May 2, 2012 2:42 PM EDT

Researchers using mice to explore the initial triggers of Alzheimer's disease believe they've fingered a prime suspect -- a highly toxic protein that converts other proteins into more toxic forms in a behavior that mimics mad cow disease.

These converted proteins then work in concert with another protein called tau to kill nerve cells according to a paper published in Nature on Wednesday. Nerve cell death is thought to be a primary cause of memory loss and other Alzheimer's symptoms.

Read More

FDA Approves Amyvid™ (Florbetapir F 18 Injection) for Use in Patients Being Evaluated for Alzheimer's Disease and Other Causes of Cognitive Decline

Amyvid is the first and only radioactive diagnostic agent approved for PET imaging of beta-amyloid neuritic plaques in the living brain

INDIANAPOLIS, April 6, 2012 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Avid Radiopharmaceuticals, Inc., a wholly owned subsidiary of Lilly, today announced the U.S. Food and Drug Administration (FDA) approval of Amyvid™, a radioactive diagnostic agent indicated for brain imaging of beta-amyloid plaques in patients with cognitive impairment who are being evaluated for Alzheimer's Disease and other causes of cognitive decline.[1] Amyvid binds to amyloid plaques, a hallmark characteristic of Alzheimer's Disease,[2],[3],[4] and is detected using PET scan images of the brain.

Read More

Irregular Heartbeat May Predict Mental Decline in Some

MONDAY, Feb. 27 (HealthDay News) 

Abnormal heart rhythm linked to brain function problems in heart disease patients, study finds a potentially dangerous heart rhythm problem called atrial fibrillation is a strong predictor of mental and physical decline in older people at risk for heart disease, new research suggests.

Read More

More Articles...

Page 1 of 15

Start
Prev
1





Forgot login?
No account yet? Register

Where are we with biomarker diagnosis and other tests for Alzheimer's Disease?